HC Wainwright Analysts Reduce Earnings Estimates for INO

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) – Equities research analysts at HC Wainwright lowered their Q4 2027 earnings per share (EPS) estimates for shares of Inovio Pharmaceuticals in a research note issued to investors on Thursday, August 13th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.03 for the quarter, down from their prior forecast of $0.07. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Inovio Pharmaceuticals’ current full-year earnings is ($0.99) per share.

A number of other analysts also recently issued reports on INO. Zacks Research raised Inovio Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday. Jefferies Financial Group upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “positive” rating and upped their target price for the company from $1.80 to $3.00 in a report on Thursday. Piper Sandler reiterated an “overweight” rating and set a $4.00 price target on shares of Inovio Pharmaceuticals in a research note on Monday, August 3rd. Wall Street Zen lowered Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, June 21st. Finally, Weiss Ratings raised Inovio Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 29th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $3.17.

Inovio Pharmaceuticals Trading Up 16.9%

Shares of INO opened at $0.90 on Friday. The firm has a market capitalization of $74.05 million, a price-to-earnings ratio of -0.99 and a beta of 1.52. The firm’s fifty day simple moving average is $1.03 and its 200-day simple moving average is $1.30. Inovio Pharmaceuticals has a twelve month low of $0.56 and a twelve month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last released its earnings results on Wednesday, August 12th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Focus Partners Wealth purchased a new position in shares of Inovio Pharmaceuticals in the 3rd quarter valued at approximately $33,000. Raymond James Financial Inc. grew its position in Inovio Pharmaceuticals by 4,396.0% in the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 16,309 shares during the last quarter. Jacobs Levy Equity Management Inc. acquired a new position in Inovio Pharmaceuticals in the 3rd quarter valued at $41,000. Zacks Investment Management purchased a new position in Inovio Pharmaceuticals during the 3rd quarter worth $46,000. Finally, Caitong International Asset Management Co. Ltd boosted its holdings in shares of Inovio Pharmaceuticals by 752.9% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock valued at $36,000 after acquiring an additional 18,160 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.